Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement

Immunovant (IMVT) shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. I downgrade IMVT from "Strong Buy" to "Buy" due to competitive TED landscape and de-emphasis on batoclimab, despite robust upcoming catalysts. IMVT-1402 aims to address unmet needs in relapsed or uncontrolled GD patients, with pivotal data readouts expected in 2027 for additional indications like Myasthenia Gravis and difficult-to-treat rheumatoid arthritis.

Seeking Alpha • Dec 12, 2025

Immunovant Announces Pricing of $550 Million Common Stock Financing

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transaction. Roivant Sciences Ltd., the Company's controlling stockholder, has agreed to purchase shares in the offering. All of the shares are to be sold by Immunovant.

GlobeNewsWire • Dec 11, 2025

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.

Zacks Investment Research • Nov 11, 2025

Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript

Immunovant, Inc. ( IMVT ) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant Sciences Ltd.

Seeking Alpha • Nov 10, 2025

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Study in uncontrolled Graves' disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment data IMVT-1402 development is progressing with potentially registrational studies in GD, myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA) and Sjögren's disease (SjD) remains on track Immunovant remains on track for the first of the two batoclimab Phase 3 thyroid eye disease (TED) studies to read out before the end of calendar year 2025. However, due to evolving competitive dynamics, the Company anticipates sharing topline results from both TED studies concurrently in the first half of calendar year 2026 Current cash balance provides runway for announced indications through GD readout expected in 2027 NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the second quarter ended September 30, 2025.

GlobeNewsWire • Nov 10, 2025

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.

GlobeNewsWire • Oct 27, 2025

Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 10, 2025

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.

Zacks Investment Research • Sep 4, 2025

Why Immunovant Stock Blasted Higher Today

Wednesday might have been a Hump Day of a slog to some investors, but not for those holding shares of Immunovant (IMVT 10.82%). On some rather encouraging news from the laboratory, the clinical-stage biotech's shares gained almost 11% in value, easily topping the 0.5% rise of the benchmark S&P 500 (^GSPC 0.51%).

The Motley Fool • Sep 3, 2025

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared an abstract with six-month off-treatment data in uncontrolled Graves' disease (GD) patients treated with batoclimab for 24 weeks, to be presented at the 2025 Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025.

GlobeNewsWire • Sep 3, 2025